首页> 美国卫生研究院文献>Frontiers in Pharmacology >Interpretation the Hepatotoxicity Based on Pharmacokinetics Investigated Through Oral Administrated Different Extraction Parts of Polygonum multiflorum on Rats
【2h】

Interpretation the Hepatotoxicity Based on Pharmacokinetics Investigated Through Oral Administrated Different Extraction Parts of Polygonum multiflorum on Rats

机译:口服何首乌不同提取部位对大鼠的药代动力学研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The liver injury induced by Polygonum multiflorum (PM) used for clinical treatment has recently received widespread attention. This study aimed to determine the hepatotoxicity of PM through pharmacokinetics studies. The extract of PM was separated to isolate the anthraquinone fraction, the tannin and polysaccharide fraction, the hydroxystilbene fraction, and the combined anthraquinone fraction. A rapid LC-MS/MS method was developed and validated to simultaneously analyze 2,3,5,4′-tetrahydroxystilbene-2-O-β-glucoside (TSG), emodin-8-O-β-D-glucopyranoside (EDG), and emodin in rat plasma, and was applied to the pharmacokinetics (PK) studies. The hepatotoxicity of different extracted parts of PM was evaluated through the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), total bilirubin (TBil), direct bilirubin (DBil), and indirect bilirubin (IBil) in rat serum. The results showed that liver injury occurred in all the treated groups and that the hepatotoxicity performance of the total extract was different from other groups. The pharmacokinetic studies showed that the Cmax, Tmax, AUC, t1/2, and MRT of the major compounds of different extracted parts were significantly different in rat plasma at same dosage. Emodin-O-hex-sulfate, tetrahydroxystilbene-O-(galloyl)-hex, emodin (original and generated through EDG deglycosylation), and other free anthraquinones might be responsible for the hepatotoxicity of PM in vivo. PM extracts produced inhibitory effects on drug metabolic enzymes, include CYP3A4, CYP2C19, CYP2E1, UGT1A1, etc. And these effects may be related to its hepatotoxicity and pharmacokinetic behavior different. This information on hepatotoxicity and the pharmacokinetic comparison may be useful to understand the toxicological effects of PM.
机译:用于临床治疗的何首乌(PM)引起的肝损伤近来受到广泛关注。这项研究旨在通过药代动力学研究确定PM的肝毒性。分离PM的提取物以分离蒽醌部分,单宁和多糖部分,羟基二苯乙烯部分以及合并的蒽醌部分。建立了快速LC-MS / MS方法并进行了验证,可同时分析2,3,5,4'-四羟基sti-2-O-β-葡萄糖苷(TSG),大黄素8-O-β-D-吡喃葡萄糖苷(EDG) )和大黄素在大鼠血浆中的含量,并应用于药代动力学(PK)研究。通过丙氨酸氨基转移酶(ALT),天冬氨酸氨基转移酶(AST),碱性磷酸酶(ALP),总胆红素(TBil),直接胆红素(DBil)和间接胆红素(IBil)的水平评估PM不同提取部位的肝毒性在大鼠血清中。结果显示,所有治疗组均发生肝损伤,总提取物的肝毒性表现与其他组不同。药代动力学研究表明,在相同剂量的大鼠血浆中,不同提取部位的主要化合物的Cmax,Tmax,AUC,t1 / 2和MRT显着不同。大黄素-O-己硫酸盐,四羟基sti-O-(galloyl)-己糖,大黄素(原始和通过EDG脱糖基化产生)和其他游离蒽醌可能对体内PM的肝毒性负责。 PM提取物对药物代谢酶产生抑制作用,包括CYP3A4,CYP2C19,CYP2E1,UGT1A1等。这些作用可能与其肝毒性和药代动力学行为不同有关。有关肝毒性和药代动力学比较的信息可能有助于理解PM的毒理作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号